Life
South Korea Approves First Domestic GLP-1 Obesity Injection
· Reviewed by the editor
South Korea's Ministry of Food and Drug Safety has approved 'Epe Auto-Injector', the nation's first homegrown GLP-1 obesity treatment developed by Hanmi Pharmaceutical. Expected to launch as early as late October, the drug is projected to cost around 100,000 KRW (~$71 USD) monthly, significantly lower than foreign alternatives like Wegovy and Mounjaro. Clinical trials over 40 weeks showed an average weight reduction of approximately 9.75 percent.
So what
If you follow Korea's healthcare and pharmaceutical landscape, anticipate more accessible GLP-1 weight-loss prescription options at local clinics before year-end.